Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00935467 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00935467 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 12 participants.
The verdict
NCT00935467, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
To characterize the steady-state pharmacokinetics (PK) of 2.5 mg saxagliptin administered twice daily with meals to healthy subjects
Interventions
- DRUG Saxagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-07 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00935467
The ClinicalTrials.gov registry entry for NCT00935467 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Saxagliptin is the first listed.
NCT00935467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00935467 about?
NCT00935467 is a clinical study titled "Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects". To characterize the steady-state pharmacokinetics (PK) of 2.5 mg saxagliptin administered twice daily with meals to healthy subjects
What is the current status of trial NCT00935467?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-07. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00935467?
The interventions under investigation include: Saxagliptin (DRUG).
Who is sponsoring clinical trial NCT00935467?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.